Location: Solmed Polyclinic (Zagreb)
Study Drug: Dual GLP-1 and amylin receptor agonist that is expected to have a stronger effect on glycemic control and reduction in body weight compared to regular GLP-1 agonists.
Main Inclusion Criteria: Patients over 18 years old with type 2 diabetes who, despite metformin therapy (with or without SGLT-2 inhibitors), have poorly controlled diabetes (HbA1c > 7.0%).
Status: In preparation
Start of Patient Enrollment: August 2024.
